Pregabalin Capsule
Product Images NDC 55700-774

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 55700-774). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (100mg)

Label for PREGABALIN 100 MG capsules by Quality Care Products, LLC. The label indicates a package size of 30 capsules, with storage instructions and warning that the drug may be habit forming. It includes the NDC 55700-0773-30 and notes that each capsule contains pregabalin. Manufacturer details include Rising Pharmaceuticals, Inc. and Laurus Labs Limited.*

FDA Label Image

Image Description (150mg)

Label for Pregabalin 150 mg capsules, containing 30 capsules per bottle. Distributed by Quality Care Products, LLC. The label warns the medication may be habit forming and is for prescription use only. It includes storage instructions and manufacturer details: made by Laurus Labs Limited in India for Rising Pharmaceuticals, Inc.*

FDA Label Image

Image Description (50mg)

Label for PREGABALIN 50 MG capsules, with a package quantity of 30 capsules. The product is packaged and distributed by Quality Care Products, LLC, Holland, OH. The label includes storage instructions, a habit-forming warning, and manufacturer details: manufactured for Rising Pharmaceuticals, Inc. and by Laurus Labs Limited, India. The capsules are described as white.*

FDA Label Image

Image Description (75mg)

Label of Pregabalin 75 mg capsules distributed by Quality Care Products, LLC. The label indicates a package containing 30 capsules. It includes storage instructions (store at 68 to 77 degrees F) and a warning that the drug may be habit-forming. The label also displays NDC 55700-775-30, GTIN, and manufacturing details by Laurus Labs Limited, India and distribution by Rising Pharmaceuticals, NJ.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure diagram of pregabalin showing its molecular framework with labeled amino and carboxyl functional groups.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula depicting creatinine clearance (CLCr) calculation, involving age, weight, serum creatinine, and a factor for female patients. The formula is not directly related to the product but is commonly used in pharmacokinetic assessments.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 200 mg, 100 mg, and 25 mg three times a day, compared to a placebo. The graph shows four lines representing each treatment group.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line chart comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg three times a day versus placebo. The graph shows two trend lines, with the Pregabalin group consistently exhibiting higher percentage of patient improvement across increasing pain improvement thresholds.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg taken twice a day, compared to placebo. The graph illustrates dose-dependent improvements in pain relief over a range of pain improvement percentages.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph illustrates higher improvement percentages for Pregabalin dosages compared to placebo across the pain improvement range.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph illustrates patient improvement response rates across different levels of pain improvement percentage.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

Bar chart comparing responder rates (%) across different doses of pregabalin and placebo in two clinical studies labeled Study E1 and Study E3. The x-axis lists treatment groups including placebo and varying daily doses of pregabalin (50 mg, 150 mg, 300 mg, 600 mg, with BID or TID noted). The y-axis represents responder rate percentages from 0% to 60%. Study E1 shows increasing responder rates with higher doses, and Study E3 compares placebo with 600 mg/day pregabalin doses, showing higher response rates with active treatment.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph depicting seizure reduction (median % change from baseline) on the y-axis versus dose in mg/day on the x-axis. It includes four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, showing increasing seizure reduction with higher doses up to 600 mg/day. Several p-values indicating significance are noted alongside data points.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Multiple treatment groups are shown, including Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and a placebo group, each represented by different line styles. Vertical reference lines are present at 30%, 50%, and 60% pain improvement.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival plot showing the estimated percentage of subjects without LTR (loss to response) over 180 days, comparing Pregabalin and Placebo treatments. The y-axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis represents time in days from 0 to 180. The Pregabalin group is shown with a solid line, and the Placebo group with a dashed line, indicating higher survival without LTR in the Pregabalin group over time.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing the percent of subjects improved for Pregabalin versus Placebo over percent improvement from baseline to Week 12 BOCF. The x-axis represents percent improvement from baseline, and the y-axis shows the percent of subjects improved. Pregabalin demonstrates higher subject improvement percentages across the range compared to placebo.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to week 16 BOCF between Pregabalin and placebo groups. The graph shows the percent improved on the vertical axis and percent improved from baseline to week 16 on the horizontal axis, with Pregabalin represented by a solid line and placebo by a dotted line.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.